An important development in the worldwide treatment and care of HIV-infected individuals was announced earlier this week. Read on to find out what this means for HIV treatment practices moving forward…
In the past few months, support for HIV pre-exposure prophylaxis (PrEP; Truvada) has grown substantially. The CDC and WHO now endorse it, as does New York State Governor Cuomo who recently announced a multi-pronged plan to reduce the rate of new HIV infections in the state by 75% before 2020. However, the role of PrEP in curbing HIV transmission is still hotly debated – who should take it, who should pay for it, and whether or not it will work on a population level. Its price tag is about $10,000/year to insurers, it requires daily adherence for maximum benefit, and involves periodic testing to monitor a patient’s HIV status. Part of the concern is that PrEP’s effectiveness may be affected by two behavioral phenomena often experienced in health promotion: self-selection and risk compensation. (more…)
A newly released study demonstrates that approximately one third of Alzheimer’s cases worldwide are attributable to seven modifiable risk factors: depression, physical inactivity, diabetes, midlife hypertension, midlife obesity, smoking, and low educational attainment. The largest proportion of cases was attributed to physical inactivity, which affects more than half of all Americans. Depression, which affects approximately 14.8 million Americans, accounted for approximately one in ten cases of Alzheimer’s disease globally.
These findings highlight the urgent need for more investment in prevention – and specifically in a holistic approach to health promotion, which includes mental health. (more…)